(NASDAQ: IMTX) Immatics Nv's forecast annual revenue growth rate of 13.76% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.06%.
Immatics Nv's revenue in 2024 is $58,692,391.On average, 3 Wall Street analysts forecast IMTX's revenue for 2024 to be $4,938,935,410, with the lowest IMTX revenue forecast at $3,282,182,480, and the highest IMTX revenue forecast at $5,985,305,682. On average, 2 Wall Street analysts forecast IMTX's revenue for 2025 to be $6,380,657,557, with the lowest IMTX revenue forecast at $3,282,182,480, and the highest IMTX revenue forecast at $9,479,132,634.
In 2026, IMTX is forecast to generate $7,097,709,030 in revenue, with the lowest revenue forecast at $7,097,709,030 and the highest revenue forecast at $7,097,709,030.